AstraZeneca: all 4,196 studies
Page 20 of 42. Open to participants first (299), then studies with results posted, then the rest; newest registration first within each.
- Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic ImpairmentCompletedNCT05961397Phase 1
- Phase 1 Study to Determine the Metabolism and Clearance of BaxdrostatCompletedNCT05961384Phase 1
- Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLCompletedNCT05958134
- Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..CompletedNCT05955183Phase 1
- Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient CharacteristicsCompletedNCT05953701
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingNCT05952557Phase 3
- A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
- Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDERCompletedNCT05945108
- BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsActive, not recruitingNCT05943106Phase 3
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
- A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiAActive, not recruitingNCT05939128
- A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.CompletedNCT05938270Phase 1
- RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in CanadaCompletedNCT05933044
- OPTIMISE-CKD Drug UtilizationCompletedNCT05932901
- Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma CentresCompletedNCT05932849
- Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult ParticipantsCompletedNCT05932641Phase 1
- A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or ProcedureWithdrawnNCT05926349Phase 3
- Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Active, not recruitingNCT05925803Phase 3
- Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active, not recruitingNCT05925530Phase 2
- A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)CompletedNCT05924880Phase 3
- Tezepelumab PRO StudyCompletedNCT05922891
- A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693CompletedNCT05919069Phase 1
- A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian FederationCompletedNCT05918042
- Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in ChinaCompletedNCT05917951
- Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in GreeceCompletedNCT05915182
- HER2-low Unresectable and/or Metastatic Breast Cancer in RussiaCompletedNCT05913440
- HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in RussiaCompletedNCT05905939
- Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)CompletedNCT05903989
- Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With OndexxyaCompletedNCT05898412
- HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in RussiaCompletedNCT05892926
- Non-interventional Study of Patients With PN NF1 Starting Selumetinib in RussiaTerminatedNCT05891847
- A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male SubjectsCompletedNCT05888207Phase 1
- CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in RussiaActive, not recruitingNCT05887011
- Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05883644Phase 3
- Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response StudyCompletedNCT05872958Phase 1
- To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian PatientsCompletedNCT05866276
- A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.TerminatedNCT05864391Phase 1
- Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)CompletedNCT05862545
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy ParticipantsCompletedNCT05848440Phase 1
- A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During PregnancyWithdrawnNCT05847140
- Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompletedNCT05835778
- Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompletedNCT05826366
- Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled StudyWithdrawnNCT05825365Phase 2
- A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy ParticipantsCompletedNCT05818514Early Phase 1
- An ADME Study of [14C]AZD0780 in Healthy Male SubjectsCompletedNCT05817461Phase 1
- Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.Active, not recruitingNCT05817110
- A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsActive, not recruitingNCT05801029Phase 2
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese SubjectsTerminatedNCT05794672Phase 1
- Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female SubjectsCompletedNCT05790304Phase 1
- A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.CompletedNCT05787002Phase 1
- A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult ParticipantsCompletedNCT05780645Phase 1
- Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic HypoparathyroidismActive, not recruitingNCT05778071Phase 3
- A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian CancerCompletedNCT05775549
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)Active, not recruitingNCT05771480Phase 3
- A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male SubjectsCompletedNCT05768360Phase 1
- Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy ParticipantsCompletedNCT05755932Phase 3
- Pharmacokinetics of Mitiperstat in Participants With Hepatic ImpairmentCompletedNCT05751759Phase 1
- Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy ParticipantsCompletedNCT05751642Phase 1
- Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).CompletedNCT05742802Phase 3
- Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)CompletedNCT05734339
- TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)Active, not recruitingNCT05729711
- Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy VolunteersCompletedNCT05714254Phase 1
- eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health ServicesCompletedNCT05712096
- Potential Drug Interaction Between ALXN2040 and RosuvastatinCompletedNCT05708573Phase 1
- Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil StudyCompletedNCT05697705
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186TerminatedNCT05694741Phase 1
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaActive, not recruitingNCT05692180Phase 3
- Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)CompletedNCT05687877
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05687266Phase 3
- Early Access Program for ALXN1840 in Patients With Wilson DiseaseNo longer availableNCT05686564
- MEDI5752 in Japanese Patients With Advanced Solid Tumors.CompletedNCT05685472Phase 1
- A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.Active, not recruitingNCT05683977
- US Selumetinib RegistryTerminatedNCT05683678
- LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)CompletedNCT05677308
- A Study for Observing Severe Asthma in Patients Treated With TezepelumabCompletedNCT05677139
- A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy ParticipantsTerminatedNCT05668936Phase 1
- eVusheld Assessment reaL wORld Effectiveness at UPMCCompletedNCT05667116
- Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyCompletedNCT05667064
- Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyCompletedNCT05665374
- eVusheld Assessment reaL wORld Effectiveness in the VA Health SystemCompletedNCT05663957
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.CompletedNCT05662033Phase 1
- First in Human Study of AZD9592 in Solid TumorsActive, not recruitingNCT05647122Phase 1
- Retention Rate of Acalabrutinib in a Non-interventional SettingActive, not recruitingNCT05645172
- A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.TerminatedNCT05644600Phase 1
- Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisActive, not recruitingNCT05644561Phase 3
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.Active, not recruitingNCT05637112
- Real-world Dapagliflozin Experience in Patients With Heart Failure in GreeceCompletedNCT05635331
- A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.CompletedNCT05630677Phase 1
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Active, not recruitingNCT05629585Phase 3
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)Active, not recruitingNCT05629234Phase 3
- Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma PatientsCompletedNCT05603845
- An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast CancerTerminatedNCT05592483
- Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisActive, not recruitingNCT05583227Phase 3
- Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 PharmacokineticsCompletedNCT05578846Phase 1
- Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid MalignanciesCompletedNCT05573724Phase 1
- eVusheld Assessment reaL wORld Effectiveness in DoD Health SystemCompletedNCT05569408
- Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver DiseaseCompletedNCT05560607Phase 1
- Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCActive, not recruitingNCT05557838Phase 3
- Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisActive, not recruitingNCT05556096Phase 3